Sort
48,018 grants matching “immunotherapy”
Core C: Cell Processing and Sample Collection
$398,042Cameron John Turtle · Fred Hutchinson Cancer Research Center · P01 · FY2018 · CA
Development of Novel CD180-Based Cancer Immunotherapeutics
$398,040Edward A Clark · Abacus Bioscience Inc · R41 · FY2022 · CA
Full-length sequencing of individual RNAs from heterogeneous samples
$398,040William S Agnew · Phaeno Inc · R43 · FY2022 · HG
Development of first-in-class antagonists of the retinoid pathway as novel oral immunotherapies for solid cancers
$398,040Mark Esposito · Kayothera Inc. · R43 · FY2023 · CA
Monitoring Immunotherapy Response via Gene Silencing Landscapes in Cell-Free DNA
$398,040Michael T Barrett · Binary Genomics, Inc. · R43 · FY2023 · CA
Chimeric antigen receptor-modified iNKT cell therapy for CD7+ malignancies
$398,040Xianzheng Zhou · Tinkeso Therapeutics Inc · R43 · FY2023 · CA
Development of Localized Triple-Negative Breast Cancer Immunotherapy
$398,039David Zaharoff · Intra Therapeutics, Llc · R41 · FY2025 · CA
Spatial and Temporal Progression of Amyloid Angiopathy
$398,031Matthew P Frosch · Massachusetts General Hospital · R01 · FY2008 · AG
A Wireless Multi-function Microscope for Lifetime Imaging of the Brain Tumor Vasculome
$398,030Arvind P Pathak · Johns Hopkins University · R01 · FY2024 · CA
An interactive analysis toolkit for single cell RNA-seq in cancer research
$397,988William Evan Johnson · Boston University Medical Campus · U01 · FY2017 · CA
Vaccine strategies for HIVAIDS
$397,966Jay A Berzofsky · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Allogeneic BAFF Ligand Based CAR T Cells as a Novel Therapy for B Cell Malignancies
$397,934Andrew Kyle Lewis · Luminary Therapeutics, Inc. · R44 · FY2023 · CA
Preclinical Evaluation of a Novel ADAM10 Modulator to Treat ColorectalCancer
$397,916Prem Khovabutr Premsrirut · Mirimus, Inc. · R41 · FY2023 · CA
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors
$397,908John H Sampson · Duke University · R01 · FY2017 · NS
The Evaluation of Novel Therapeutics for Genitourinary Malignancies
$397,882William Laurence Dahut · Division Of Clinical Sciences - Nci · Z01 · FY2008 · CA
Resource for Nonhuman Primate Immune Reagents
$397,868Francois J Villinger · University Of Louisiana At Lafayette · R24 · FY2016 · OD
Immunobiology of Myeloid and Lymphoid Cells
$397,866Dartmouth College · T32 · FY2002 · AI
Targeting cysteine import to induce ferroptotic cell death in pancreatic cancer
$397,862Kenneth P Olive · Columbia University Health Sciences · R01 · FY2023 · CA
Comparative MHC and KIR immunogenetics in the Great Apes
$397,844Peter R Parham · Stanford University · R01 · FY2017 · AI
Comparative MHC and KIR immunogenetics in the Great Apes
$397,844Peter R Parham · Stanford University · R01 · FY2019 · AI
Comparative MHC and KIR immunogenetics in the Great Apes
$397,844Peter R Parham · Stanford University · R01 · FY2020 · AI
Phase II Trial of Arimoclomol in IBM
$397,836Mazen Dimachkie · University Of Kansas Medical Center · R01 · FY2020 · FD
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses
$397,814Mark P Rubinstein · Medical University Of South Carolina · R01 · FY2020 · CA
Lymphocyte and inflammatory cytokine markers of response in the first-in-human combination of anti-PD-1 mAb and IL-15/IL-15Ra complexes and investigation of mediators of anti-tumor immune responses
$397,814John M. Wrangle · Medical University Of South Carolina · R01 · FY2021 · CA
Targeted activation of autoimmune checkpoints in B cell malignancies
$397,813Markus Mãschen · Yale University · R01 · FY2021 · CA